Should I Buy ILMN? ILMN 2026 Analysis

Should You Buy Illumina Inc (ILMN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

119.720

1 Day change

-10.40%

52 Week Range

155.530

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: the stock is technically washed-out (oversold), but momentum is still down and there’s an earnings event after-hours today that can easily overwhelm the oversold setup.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
Options positioning leans bullish (calls > puts), but implied volatility is elevated into earnings, suggesting the market is pricing a large move rather than a clean direction.
Overall call: Hold / avoid initiating a new long position today (if you already own it, this isn’t a clear add signal before earnings).

Technical Analysis

Trend/Momentum: Bearish near-term momentum.
- MACD histogram -2.354 and negatively expanding → downside momentum still building.
RSI (6): 19.803 (oversold) → conditions are stretched and could bounce, but oversold alone is not a buy signal when MACD is deteriorating.
Moving averages: Converging MAs → transition zone; not yet signaling a confirmed uptrend.
Key levels:
- Pivot: 145.10 (price well below pivot = weak)
- Support: S1 136.62 and S2 131.38 (price ~133.9 is sitting between S1/S2 → vulnerable if earnings disappoint)
- Resistance: 145.10, then 153.58
Pattern-based forward bias (given dataset): higher probability skew to -3.97% next week vs +1.68% next month, implying near-term chop/down risk remains elevated.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios are below 1 (OI PCR 0.48, volume PCR 0.56) → options market is positioned more bullish than bearish.
Volatility:
- 30D IV 57.82 vs historical vol 40.29 → options are pricing a large move (earnings premium).
- IV percentile 82.47 → IV is high relative to its recent history.
Activity: Today’s option volume 489 is below the 5D avg (807.4) and far below the 10D avg (2525.4), suggesting no broad-based surge in fresh conviction today.
Interpretation: Options lean bullish, but elevated IV into earnings implies directional risk is high and the edge for an impatient “buy now” entry is weaker.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst (QDEC 2025, after hours 2026-02-05): a beat/raise could trigger an oversold rebound.
- M&A / portfolio expansion: completed SomaLogic acquisition (up to $425M), expanding Illumina’s proteomics footprint.
- Product/transition narrative (from analyst notes): continued progress in NovaSeq X transition could support consumables growth.
- Partnership/brand halo: collaboration with San Diego Zoo (large-scale sequencing for conservation) supports strategic visibility in multiomics and large-scale sequencing use cases.

Neutral/Negative Catalysts

- Event risk is immediate: earnings after-hours today can invalidate technical levels quickly; not ideal for an impatient entry without a signal.
- Momentum remains bearish: MACD is still weakening despite oversold RSI.
- Profitability pressure (latest provided quarter): steep YoY declines in net income and EPS point to operational/earnings-quality concerns.
- Support proximity: price is close to S2 (131.38); a weak print/guidance could break support and extend the down move.
- Positioning risk: bullish skew in options (low put/call) can backfire if earnings disappoint (crowded “hope for rebound” setup).

Financial Performance

Latest provided quarter: 2025/Q3
- Revenue: $1.084B, +0.37% YoY (essentially flat growth).
- Net income: $150M, -78.72% YoY (major profitability deterioration).
- EPS: 0.97, -78.00% YoY.
- Gross margin: 67.62%, down 1.97% YoY (margin compression).
Takeaway: top line is stable, but earnings/margins weakened sharply, which helps explain why the stock can stay weak even when “oversold.”

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: broadly rising price targets in January 2026 following updates/preliminary results; sentiment has improved versus late 2025.
- Guggenheim: Buy, PT raised to $170 (from $144) and earlier to $144 (from $114).
- Stifel: Buy, PT $155 (from $135).
- Evercore ISI: Outperform, PT $155 (from $142).
- TD Cowen: Hold, PT $140 (from $115).
- Canaccord: Hold, PT $150 (from $130) and earlier $130 (from $112).
- JPMorgan: Neutral, PT $130 (from $105).
- Barclays: Underweight, PT $110 (from $100).
Wall Street pros (bull case): improving end-market tone, NovaSeq X/consumables ramp, and strategic expansion (proteomics) supporting a multi-year recovery narrative.
Wall Street cons (bear case): lingering skepticism shown by multiple Holds/Neutral and an Underweight; profitability and margin trajectory are the key swing factors.
Influential/political trading check: No recent congress trading data available; hedge funds and insiders show neutral recent trend (no strong confirmatory buying).

ILMN Should I Buy